Renal Cell Carcinoma: Interpreting Survival and Response Outcomes

In this segment, Dr. Elizabeth Plimack and Dr. Sundhar Ramalingam discuss how clinicians interpret long-term outcomes from first-line clinical trials in renal cell carcinoma, including studies such as CLEAR. The conversation focuses on the relationship between overall survival, depth of response, and durability of benefit when evaluating treatment options. Dr. Ramalingam explains that while overall survival remains a critical endpoint, response depth and durability provide additional context that can inform clinical decision-making, particularly in patients who require rapid disease control. The discussion highlights how these endpoints should be considered together rather than in isolation, as each contributes to a more comprehensive understanding of treatment benefit. The segment also emphasizes the importance of applying trial data thoughtfully in clinical practice, taking into account patient characteristics and disease burden when selecting first-line therapy in renal cell carcinoma.